| Symbol | AMRX |
|---|---|
| Name | AMNEAL PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 400 CROSSING BOULEVARD,3RD FLOOR, BRIDGEWATER, New Jersey, 08807, United States |
| Telephone | +1 908 947-3120 |
| Fax | — |
| — | |
| Website | https://www.amneal.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The companys reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and the Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. Additional info from NASDAQ: |
New Form DEFA14A - Amneal Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0001193125-26-170732 <b>Size:</b> 2 MB
Read moreNew Form DEFA14A - Amneal Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0001193125-26-170540 <b>Size:</b> 40 KB
Read moreNew Form DEFA14A - Amneal Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0001193125-26-170531 <b>Size:</b> 815 KB
Read moreNew Form DEFA14A - Amneal Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0001193125-26-170525 <b>Size:</b> 27 KB
Read moreNew Form DEFA14A - Amneal Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0001193125-26-170519 <b>Size:</b> 12 MB
Read more(10% Negative) AMNEAL PHARMACEUTICALS, INC. (AMRX) Announces Business Combination
Read moreKashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader
Read moreAmneal Pharmaceuticals, Inc. - Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
Read moreAmneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
Read moreNew Form DEFA14A - Amneal Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0001193125-26-168237 <b>Size:</b> 1 MB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06765668 | A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Partic… | Phase4 | Parkinson Disease | Recruiting | 2025-02-12 | 2026-08-06 | ClinicalTrials.gov |
| NCT06467201 | SAD Study to Evaluate Safety, Tolerability, and Pharmacokinetic Profile of AMN1… | Phase1 | Healthy Postmenopausal Women | Completed | 2024-06-03 | 2025-03-12 | ClinicalTrials.gov |
| NCT05401357 | Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic So… | Phase3 | Glaucoma, Open-Angle | Recruiting | 2022-06-29 | 2022-12-01 | ClinicalTrials.gov |
| NCT02940561 | BE Study in Patients - Methotrexate Tablets | Phase1 | Psoriasis | Unknown | 2016-08-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02110368 | Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Mete… | Phase3 | Primary Hypogonadism | Completed | 2014-03-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT02103322 | Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myelo… | Phase2 | Chronic Myeloid Leukemia | Completed | 2014-02-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT02125253 | Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray,… | Phase3 | Seasonal Allergic Rhinitis | Completed | 2014-01-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT02072954 | Bioequivalence Fasting Study in Patients | Phase2 | Schizophrenia | Completed | 2013-11-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01779947 | Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, 1… | Phase3 | Atrophic Vaginitis Due to Menopause | Completed | 2012-03-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01067001 | Minocycline HCl Extended Release Tablets 135 mg Oral Bioequivalence Study | — | Fasting | Completed | 2009-09-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00404989 | Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any M… | — | HIV Infections | Recruiting | 1989-01-01 | 2099-01-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| CREXONT ER | DRUG | Phase PHASE4 | Parkinson Disease | RECRUITING | NCT07138560 |
| KSHN001126 600mg | DRUG | Phase PHASE1 | Healthy Postmenopausal Women | COMPLETED | NCT06467201 |
| KSHN001126 300mg | DRUG | Phase PHASE1 | Healthy Postmenopausal Women | COMPLETED | NCT06467201 |
| KSHN001126 150mg | DRUG | Phase PHASE1 | Healthy Postmenopausal Women | COMPLETED | NCT06467201 |
| LUMIGAN® (bimatoprost ophthalmic solution) 0.01% | DRUG | Phase PHASE1 | Open-angle Glaucoma | RECRUITING | NCT06267274 |
| Bimatoprost Ophthalmic Solution, 0.01% | DRUG | Phase PHASE1 | Open-angle Glaucoma | RECRUITING | NCT06267274 |
| Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution) | DRUG | Phase PHASE3 | Glaucoma, Open-Angle | RECRUITING | NCT05401357 |
| Test - Bimatoprost 0.01% Ophthalmic Solution | DRUG | Phase PHASE3 | Glaucoma, Open-Angle | RECRUITING | NCT05401357 |
| Methotrexate - DAVA | DRUG | Phase PHASE1 | Psoriasis | UNKNOWN | NCT02940561 |
| Methotrexate - Amneal | DRUG | Phase PHASE1 | Psoriasis | UNKNOWN | NCT02940561 |
| Placebo Nasal Spray | DRUG | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT02125253 |
| Nasonex Nasal Spray, 50 mcg | DRUG | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT02125253 |
| Mometasone Furoate Nasal Spray, 50 mcg | DRUG | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT02125253 |
| Vehicle Diclofenac Sodium Topical Gel | DRUG | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT02121002 |
| Voltaren Topical Gel, 1% | DRUG | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT02121002 |
| Diclofenac Sodium Topical Gel, 1% | DRUG | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT02121002 |
| AndroGel (testosterone gel) 1.62% Metered-Dose Pump | DRUG | Phase PHASE3 | Primary Hypogonadism | COMPLETED | NCT02110368 |
| Testosterone Topical Gel, 1.62% Metered Pump | DRUG | Phase PHASE3 | Primary Hypogonadism | COMPLETED | NCT02110368 |
| Imatinib Mesylate Tablets, 400 mg | DRUG | Phase PHASE2 | Chronic Myeloid Leukemia | COMPLETED | NCT02103322 |
| Asenapine Sublingual Tablets 10 mg | DRUG | Phase PHASE2 | Schizophrenia | COMPLETED | NCT02072954 |
| placebo | DRUG | Phase PHASE3 | Atrophic Vaginitis Due to Menopause | COMPLETED | NCT01779947 |
| Estradiol Vaginal Tablets 10 mcg | DRUG | Phase PHASE3 | Atrophic Vaginitis Due to Menopause | COMPLETED | NCT01779947 |
| Phenazopyridine Hydrochloride Tables, USP 200 mg | DRUG | Phase PHASE3 | Uncomplicated Urinary Tract Infections | COMPLETED | NCT01650051 |
| Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg | DRUG | Phase PHASE3 | Uncomplicated Urinary Tract Infections | COMPLETED | NCT01650051 |
| Placebo | DRUG | Phase PHASE3 | Pain | COMPLETED | NCT01064024 |
| Phenazopyridine Hydrochloride | DRUG | Phase PHASE3 | Pain | COMPLETED | NCT01064024 |